Scrip M&A Podcast: Will the FDA Staff Cuts Affect Biopharma M&A Activity?

Citeline Podcasts
01/05/2025 40 min
Scrip M&A Podcast: Will the FDA Staff Cuts Affect Biopharma M&A Activity?

Listen "Scrip M&A Podcast: Will the FDA Staff Cuts Affect Biopharma M&A Activity?"

Descargar episodio Ver en sitio original

Episode Synopsis

Scrip senior writer Joseph Haas discusses the potential impact of the recent FDA staff cuts with attorneys Andrew Goodman of Paul Hastings LLP and Alan Minsk of Arnall Golden Gregory, as well as Naya Therapeutics CEO Daniel Teper

More episodes of the podcast Citeline Podcasts

Datamonitor Healthcare Podcast: ESMO 2025 12/11/2025
Scrip 五件必知要闻: 药闻周析 - 全球制药风云聚焦 (Chinese-language podcast) 10/11/2025
Scrip's Five Must-Know Things - Nov. 10, 2025 10/11/2025
Drug Fix: Examining George Tidmarsh’s Departure As Head Of US FDA’s Drug Center 07/11/2025
Podcast: Beyond The Checkpoint — Next-Gen Strategies In Immuno-Oncology 06/11/2025
Scrip 五件必知要闻: 药闻周析 - 全球制药风云聚焦 (Chinese-language podcast) 04/11/2025
Scrip's Five Must-Know Things - Nov. 4, 2025 04/11/2025
Drug Fix: US FDA Streamlines Biosimilar Development Requirements, Clarifies Inspection Reform 31/10/2025
Decoding Cell Differentiation: How AI Foundation Models Are Reshaping Regenerative Medicine 31/10/2025
Scrip M&A Podcast: What's Next For Dealmaking In The Obesity Space? 31/10/2025
© 2003-2025 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA